-
Merck KGaA Outlines Expansion Plans for US Healthcare Market with Anticipated 2025 Drug Launches
•
Germany’s Merck KGaA (ETR: MRK), a leading player in the global pharmaceutical industry, has this week unveiled its strategic plans for the US healthcare market. The company, which currently commercializes two cancer treatments in the US, is gearing up to launch two additional drugs by 2025. Furthermore, Merck anticipates continuing…
-
Hubei Topgene Biotechnology and Shanghai Genechem Partner on Drug Toxicological Safety and Clinical Research
•
Hubei Topgene Biotechnology Co., Ltd, a China-based biotechnology company, has entered into a partnership with Shanghai Genechem Co., Ltd to collaborate on integrated drug toxicological safety evaluation, clinical research translation projects, and resource allocation. The partnership aims to leverage the strengths of both companies to enhance drug development processes. Financial…
-
EMA’s CHMP Issues Positive Opinion for Roche’s Tecentriq SC Subcutaneous Formulation
•
The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has issued a positive opinion regarding the approval of Tecentriq SC (atezolizumab), the subcutaneous version of Roche’s (SWX: ROG) PD-L1 inhibitor Tecentriq. This development is a significant step forward for patients with various types of…
-
PRECEDO Secures Over RMB 100 Million in Financing to Build Living Primary Cancer Cell Bank
•
PRECEDO, a leading cell engineering specialist headquartered in Hefei, has reportedly secured more than RMB 100 million (USD 13.8 million) in a recent financing round. This capital injection, which includes investment from Sunland Fund and other financial backers, will be directed towards the construction of the renewable Living Primary Cancer…
-
Yantai Dongcheng Pharmaceutical and Eckert & Ziegler Form Joint Venture for Medical Isotopes
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a China-based pharmaceutical company, is poised to establish a joint venture (JV) with Germany’s Eckert & Ziegler Radiopharma Projekte UG. This strategic partnership aims to combine the expertise of both companies in the field of medical isotopes. Investment and JV FormationThe joint…
-
China’s National Allied Procurement Office Announces VBP Tender for Medical Consumables and 3D Printing Products
•
The National Allied Procurement Office has released a notification outlining plans for a volume-based procurement (VBP) tender, focusing on artificial lenses and sports medicine medical consumables, with an encouragement for products utilizing additive manufacturing technology, namely 3D printing, to participate. Scope of the TenderThe tender’s scope encompasses a range of…
-
Sansure Biotech Secures CE IVDR Certifications for Chemiluminescence Analyzers in the EU
•
China-based molecular diagnostics specialist, Sansure Biotech Inc., (SHA: 688289), has announced that it has received CE IVDR certifications in the European Union for two of its fully automatic chemiluminescence immunoassay analyzer products. This regulatory milestone marks a significant step forward for the company in expanding its presence in the EU…
-
Huadong Medicine Co., Ltd Secures Partnership and Commercial Rights for Yuyan’s Botulinum Toxin
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an equity investment and partnership agreement with Chongqing Yuyan Pharmaceutical Co., Ltd. This strategic alliance involves a significant investment and the acquisition of exclusive commercialization rights for Yuyan’s medical aesthetics product in key regions. Investment and Stake AcquisitionAs per the…
